Unraveling and resolving inefficient glucolipid biosurfactants production through quantitative multiomics analyses of Starmerella bombicola strains

Glucolipids (GLs) are glycolipid biosurfactants with promising properties. These GLs are composed of glucose attached to a hydroxy fatty acid through a omega and/or omega-1 glycosidic linkage. Up until today these interesting molecules could only be produced using an engineered Starmerella bombicola strain ( increment ugtB1::URA3 G9) producing GLs instead of sophorolipids, albeit with a very low average productivity (0.01 g center dot L-1 center dot h(-1)). In this study, we investigated the reason(s) for this via reverse-transcription quantitative polymerase chain reaction and Liquid chromatography-multireaction monitoring-mass spectrometry. We found that all glycolipid biosynthetic genes and enzymes were downregulated in the increment ugtB1 G9 strain in comparison to the wild type. The underlying reason for this downregulation was further investigated by performing quantitative metabolome comparison of the increment ugtB1 G9 strain with the wild type and two other engineered strains also tinkered in their glycolipid biosynthetic gene cluster. This analysis revealed a clear distortion of the entire metabolism of the increment ugtB1 G9 strain compared to all the other strains. Because the parental strain of the former was a spontaneous increment ura3 mutant potentially containing other hidden mutations, a new GL production strain was generated based on a rationally engineered increment ura3 mutant (PT36). Indeed, a 50-fold GL productivity increase (0.51 g center dot L-1 center dot h(-1)) was obtained with the new increment ugtB1::URA3 PT36 strain compared with the G9-based strain (0.01 g center dot L-1 center dot h(-1)) in a 10 L bioreactor experiment, yielding 118 g/L GLs instead of 8.39 g/L. Purification was investigated and basic properties of the purified GLs were determined. This study forms the base for further development and optimization of S. bombicola as a production platform strain for (new) biochemicals